2023-09-01 16:44:58 ET
More on Can-Fite Biopharma
- Can-Fite submits plan to FDA to have adolescents in psoriasis drug study
- Can-Fite's Namodenoson shows promising results in preclinical study on pancreatic carcinoma, shares rise 11%
- Can-Fite stock rises after discovering effect of Namodenoson in pancreatic cancer
- Can-Fite gains on EU nod to start pivotal trial for psoriasis therapy
- Seeking Alpha’s Quant Rating on Can-Fite Biopharma
- Earnings data for Can-Fite Biopharma
For further details see:
Can-Fite Biopharma discloses $100M mixed shelf offering - filing